Patents by Inventor Christopher Sinz

Christopher Sinz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmacological correctors of rhodopsin and uses thereof
    Patent number: 12697327
    Abstract: Described herein are pharmacologic correctors of rhodopsin, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating disease.
    Type: Grant
    Filed: October 27, 2025
    Date of Patent: August 4, 2026
    Assignee: Octant, Inc.
    Inventors: Jillian R. Sanzone, Tao Zheng, Stacie S. Kim, Christopher Sinz, Jean-François Fournier, Alexandre Larivee, David Tong, Brandon Groves, Ludovic Deny, Kenneth Matthew Whitmore
  • PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF
    Publication number: 20260115174
    Abstract: Described herein are pharmacologic correctors of rhodopsin, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in treating disease.
    Type: Application
    Filed: October 27, 2025
    Publication date: April 30, 2026
    Inventors: Jillian R. Sanzone, Tao Zheng, Stacie S. Kim, Christopher Sinz, Jean-François Fournier, Alexandre Larivee, David Tong, Brandon Groves, Ludovic Deny, Kenneth Matthew Whitmore
  • Inhibitors of HIF prolyl hydroxylase
    Patent number: 10208060
    Abstract: The present invention concerns compounds of formula I or a pharmaceutically acceptable salt thereof which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: February 19, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiaqiang Cai, Alejandro Crespo, John Debenham, Xiaoxing Du, Ping Liu, Rongqiang Liu, Christina B. Madsen-Duggan, Weiguo Quan, Christopher Sinz, Liping Wang
  • Inhibitors of HIF prolyl hydroxylase
    Patent number: 10000501
    Abstract: The present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: June 19, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiaqiang Cai, Vincent Colandrea, Alejandro Crespo, John Debenham, Xiaoxing Du, Deodialsingh Guiadeen, Ping Liu, Rongqiang Liu, Christina B. Madsen-Duggan, Joshua G. McCoy, Weiguo Quan, Christopher Sinz, Liping Wang
  • Inhibitors of HIF prolyl hydroxylase
    Patent number: 9969752
    Abstract: The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: May 15, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiaqiang Cai, Alejandro Crespo, Xiaoxing Du, Byron Gabriel Dubois, Deodialsingh Guiadeen, Shankaran Kothandaraman, Ping Liu, Rongqiang Liu, Weiguo Quan, Christopher Sinz, Liping Wang
  • Pyrimidone carboxamide compounds as PDE2 inhibitors
    Patent number: 9815796
    Abstract: Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: November 14, 2017
    Assignees: Merck Sharp & Dohme Corp., MSD R & D (China) Co. LTD.
    Inventors: Dong Ming Shen, Melissa Egbertson, Richard Berger, XiaoXia Qian, Yimin Qian, Bart Harper, Meng Yang, Zack Zhiqiang Guo, Vanessa L. Rada, Deping Wang, Timothy A. Cernak, Christopher Sinz, Ming Wang, Jonathan E. Wilson, Shimin Xu
  • INHIBITORS OF HIF PROLYL HYDROXYLASE
    Publication number: 20170313718
    Abstract: The present invention concerns compounds of formula I or a pharmaceutically acceptable salt thereof which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Application
    Filed: September 23, 2015
    Publication date: November 2, 2017
    Applicants: MERCK SHARP & DOHME CORP., MSD R&D (CHINA) CO., LTD.
    Inventors: JIAQIANG CAI, ALEJANDRO CRESPO, JOHN DEBENHAM, XIAOXING DU, PING LIU, RONGQIANG LIU, CHRISTINA B. MADSEN-DUGGAN, WEIGUO QUAN, CHRISTOPHER SINZ, LIPING WANG
  • INHIBITORS OF HIF PROLYL HYDROXYLASE
    Publication number: 20170240555
    Abstract: The present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Application
    Filed: September 23, 2015
    Publication date: August 24, 2017
    Applicants: MERCK SHARP & DOHME CORP., MSD R&D (CHINA) CO., LTD.
    Inventors: JIAQIANG CAI, VINCENT COLANDREA, ALEJANDRO CRESPO, JOHN DEBENHAM, XIAOXING DU, DEODIALSINGH GUIADEEN, PING LIU, RONGQIANG LIU, CHRISTINA B. MADSEN-DUGGAN, JOSHUA G. MCCOY, WEIGUO QUAN, CHRISTOPHER SINZ, LIPING WANG
  • INHIBITORS OF HIF PROLYL HYDROXYLASE
    Publication number: 20170233412
    Abstract: The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Application
    Filed: September 23, 2015
    Publication date: August 17, 2017
    Applicants: MERCK SHARP & DOHME CORP., MSD R&D (CHINA) CO., LTD.
    Inventors: JIAQIANG CAI, ALEJANDRO CRESPO, XIAOXING DU, BYRON GABRIEL DUBOIS, DEODIALSINGH GUIADEEN, SHANKARAN KOTHANDARAMAN, PING LIU, RONGQIANG LIU, WEIGUO QUAN, CHRISTOPHER SINZ, LIPING WANG
  • INHIBITORS OF HIF PROLYL HYDROXYLASE
    Publication number: 20170226120
    Abstract: The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Application
    Filed: September 23, 2015
    Publication date: August 10, 2017
    Applicants: MERCK SHARP & DOHME CORP., MSD R&D (CHINA) CO., LTD.
    Inventors: JIAQIANG CAI, ALEJANDRO CRESPO, XIAOXING DU, BYRON GABRIEL DUBOIS, PING LIU, RONGQIANG LIU, WEIGUO QUAN, CHRISTOPHER SINZ, LIPING WANG
  • PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS
    Publication number: 20170015633
    Abstract: Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: December 17, 2014
    Publication date: January 19, 2017
    Applicants: Merck Sharp & Dohme Corp., MSD R & D (China) Co. LTD.
    Inventors: Dong Ming Shen, Melissa Egbertson, Richard Berger, XiaoXia Qian, Yimin Qian, Bart Harper, Meng Yang, Zack Zhi Qiang Guo, Vanessa L. Rada, Deping Wang, Timothy A. Cernak, Christopher Sinz, Ming Wang, Jonathan E. Wilson, Shimin Xu
  • Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
    Publication number: 20080085926
    Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: October 2, 2007
    Publication date: April 10, 2008
    Inventors: John Stelmach, Emma Parmee, James Tata, Keith Rosauer, Ronald Kim, Amy Bittner, Jiang Chang, Christopher Sinz
  • Cyclic guanidines, compositions containing such compounds and methods of use
    Publication number: 20070105930
    Abstract: The present invention relates to cyclic guanidines, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.
    Type: Application
    Filed: December 15, 2004
    Publication date: May 10, 2007
    Inventors: Emma Parmee, Ronald Kim, Elizabeth Rouse, Darby Schmidt, Christopher Sinz, Jiang Chang
  • Acyl indoles, compositions containing such compounds and methods of use
    Publication number: 20070088071
    Abstract: The present invention relates to substituted indoles, compositions containing such compounds and methods of treatment The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus and related conditions.
    Type: Application
    Filed: October 13, 2006
    Publication date: April 19, 2007
    Inventors: Ronald Kim, Amy Bittner, Christopher Sinz, Emma Parmee